Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 8, 2007

View Archived Issues

AstraZeneca identifies a novel class of small molecule UMP kinase inhibitors

Odanacatib's preclinical profile reported by Merck & Co.

Novexel's NXL-101 and NXL-104 evaluated in healthy volunteers

MK-0429 activity seen in animals and humans with bone metastases

Combination of CAPOX-B and cetuximab feasible in colorectal cancer

Studies provide data on S-013420 characteristics in vitro and in pneumonia patients

VIA receives financial support for ACS substudy of VIA-2291

First patient dosed in phase III trial of AGI-003 for IBS-D

Orexo adds two new projects to its development pipeline

FDA special protocol assessment assigned to atacicept pivotal trial

New renin inhibitor SPP-676 begins phase I clinical trials

Two phase II clinical trials launched for GFT-505

Positive phase II results reported for Lu-AA-21004 in major depression

Roche files a clinical trial application for Genmab antibody

Long-acting, nonopiate analgesic drug enters THA trial

Post-infarct cardiac healing of Corgentin to be evaluated in NIH trial

New agreement on development and commercialization of THR-174

Novel treatment options for obesity described in recent Servier and Pharmacopeia patents

New agents for treating gastrointestinal disorders reported in recent patents

Four phase I/II clinical trials commence for AEG-35156

Dosing begins in phase III registration studies for clevudine

Acusphere progresses toward NDA filing for Imagify

Enrollment commences for phase I 18F-AV-133 proof-of-concept study

MacroChem acquires rights to pexiganan

Ortho-Clinical Diagnostics introduces improved sensitivity troponin I assay

Phase I results reported for rabies antibody cocktail

New anticancer agents reported in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...